跳至主要内容
临床试验/CTIS2023-505266-29-00
CTIS2023-505266-29-00招募中1 期

XT-23-01 / FIPO23

Xenothera0 个研究点目标入组 246 人开始时间: 2023年5月11日最近更新:

试验速览

阶段
1 期
状态
招募中
发起方
Xenothera
入组人数
246

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Xenothera

相似试验

进行中(未招募)
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteers
CTIS2023-504355-28-03Helsinn Healthcare S.A.74
进行中(未招募)
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteers
CTIS2023-504355-28-00Helsinn Healthcare S.A.74
进行中(未招募)
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Overweight, ObesityMedDRA version: 20.0Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861
CTIS2023-507758-34-00Rose Pharma Inc.12
进行中(未招募)
1 期
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 2 mg film-coated tablets versus reference product Fycompa 2 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions..A. (submitted trial is a bioequivalence study in healthy human subjects)MedDRA version: 20.0Level: HLGTClassification code: 10039911Term: Seizures (incl subtypes) Class: 10029205
CTIS2023-504132-18-00aboratorios Cinfa S.A.36
招募中
1 期
A Phase 1b Study of Imvotamab in Severe Systemic Lupus ErythematosusSystemic Lupus Erythematosus
CTIS2023-506499-29-00IGM Biosciences Inc.18